阿来替尼治疗转移性阳性非小细胞肺癌患者：系统评价和网状Meta分析

Alectinib for treating patients with metastatic -positive NSCLC: systematic review and network metanalysis.

作者信息

Samacá-Samacá Daniel, Prieto-Pinto Laura, Peréz Andrés Yepes, Valderrama Carolina, Hernández Fabián

机构信息

IQVIA, Real World Insights, Bogotá, Colombia.

Evidence Generation, Roche, Bogotá, Colombia.

出版信息

Lung Cancer Manag. 2023 May 23;12(2):LMT59. doi: 10.2217/lmt-2022-0018. eCollection 2023 Jun.

AIM

To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced -positive NSCLC.

METHODS

A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.

RESULTS

13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.

目的

比较阿来替尼与其他ALK抑制剂在治疗转移性或局部晚期ALK阳性非小细胞肺癌（NSCLC）患者中的疗效和安全性。

方法

截至2021年11月进行了系统的文献综述。采用频率学派方法（随机效应）进行网状荟萃分析。进行了GRADE证据概况分析。

结果

选择了13项随机对照试验。在总生存期方面，发现阿来替尼与克唑替尼相比可降低死亡风险。在无进展生存期方面，阿来替尼与克唑替尼和色瑞替尼相比可降低死亡或进展风险。根据基线脑转移情况进行的亚组分析显示，阿来替尼优于克唑替尼，与第二代和第三代抑制剂相比效果相似。与其他ALK抑制剂相比，阿来替尼显示出良好的安全性。